Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

GlobeNewswire Inc. | Sep 24, 2026 7:00 AM EDT

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November